Innovent Biologics
Innovent Biologics, also known as Innovent, is a leading biopharmaceutical company headquartered in China (CN). Founded in 2011, the company has rapidly established itself in the biopharmaceutical industry, focusing on the development, manufacturing, and commercialisation of innovative therapies for oncology, autoimmune diseases, and other serious conditions. With a strong presence in major operational regions across Asia and beyond, Innovent is recognised for its robust pipeline of monoclonal antibodies and biosimilars. Their flagship products, including the PD-1 inhibitor Tyvyt, have garnered significant attention for their unique mechanisms of action and efficacy. Innovent's commitment to research and development has positioned it as a key player in the global market, achieving notable milestones such as successful partnerships and regulatory approvals that underscore its reputation for excellence in biopharmaceutical innovation.
DitchCarbon Score
How does Innovent Biologics's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Innovent Biologics's score of 40 is higher than 64% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Innovent Biologics's reported carbon emissions
In 2024, Innovent Biologics reported total carbon emissions of approximately 14,115,290 kg CO2e, comprising 47,780 kg CO2e from Scope 1 and 14,067,510 kg CO2e from Scope 2 emissions. This marks a decrease from 2023, where total emissions were about 15,894,420 kg CO2e, with Scope 1 emissions at 65,170 kg CO2e and Scope 2 emissions at 15,829,250 kg CO2e. The company has shown a consistent commitment to monitoring and reporting its emissions, with data disclosed for both Scope 1 and Scope 2 emissions over the past few years. However, there are currently no reported Scope 3 emissions or specific reduction targets set under the Science Based Targets initiative (SBTi) or other climate pledges. Innovent Biologics, headquartered in China, continues to focus on transparency in its emissions reporting, inheriting its data from its parent company, Innovent Biologics, Inc. The absence of specific reduction initiatives or targets suggests an opportunity for the company to enhance its climate commitments in line with industry standards.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 60,540 | 00,000 | 00,000 | 00,000 |
| Scope 2 | 15,934,330 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Innovent Biologics is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
